Gyre Therapeutics, Inc. Overview
Pro stress-test →Gyre Therapeutics is a pharmaceutical company that develops and commercializes small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company is headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis including MASH in the U.S. The company represents a pivotal commercial-stage biotech with revenue-generating assets in China and late-stage pipeline programs in the US.
Strategic Profile
Pro stress-test →The recent Cullgen acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline. Cullgen brings strong drug discovery capabilities and a solid preclinical and clinical pipeline to complement Gyre's existing and highly efficient China-based manufacturing capabilities and sales team. This strategic combination positions Gyre to leverage dual geographic strengths and expand beyond organ fibrosis into oncology and pain indications.
Competitive Landscape
Pro stress-test →Gyre competes in the organ fibrosis therapeutic space against established players and specialty biotech firms. ETUARY maintains prominent market share in China's IPF market with $105.8 million in 2024 sales. The company's acquisition of Cullgen's targeted protein degradation platform expands competitive positioning into oncology and pain, differentiating from pure fibrosis competitors.
Industry Context
Gyre Therapeutics, Inc. operates in Biopharmaceutical / Specialty Pharmaceuticals - Organ Fibrosis Therapeutics & Oncology.
Key facts
Founded: 2002 · Headquarters: San Diego, California · Employees: 579 · Revenue: $105.8M (Gyre Pharma 2024) · Market cap: $799.6M